Cargando…
Inhibition of hepatic microsomal triglyceride transfer protein – a novel therapeutic option for treatment of homozygous familial hypercholesterolemia
Familial hypercholesterolemia (FH) is an autosomal dominant disease caused by mutations in the low-density lipoprotein (LDL)-receptor gene (LDLR). Patients with homozygous FH (hoFH) have inherited a mutated LDLR gene from both parents, and therefore all their LDL-receptors are incapable of functioni...
Autores principales: | Vuorio, Alpo, Tikkanen, Matti J, Kovanen, Petri T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018418/ https://www.ncbi.nlm.nih.gov/pubmed/24851052 http://dx.doi.org/10.2147/VHRM.S36641 |
Ejemplares similares
-
Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021) -
Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2020) -
Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters
por: Vuorio, Alpo, et al.
Publicado: (2018) -
Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
por: Stefanutti, Claudia
Publicado: (2020) -
Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke
por: Vuorio, Alpo, et al.
Publicado: (2021)